Swiss allergy therapy convinces
Cytos Biotechnology presents promising results in a study of a new therapy against allergy and asthma.
The results showed that six weekly injections of CYT003-QbG10 were safe, well tolerated and reduced rhinoconjunctivitis symptoms in daily life compared to placebo. Allergy diaries served as an additional read-out parameter of this study and patients filled in diary cards about their daily nasal, conjunctival, and bronchial symptoms as well as the use of rescue medication for two consecutive weeks at different time points.
The study participants returned these diary cards for analysis after the recently completed six month follow-up visits. The average combined symptom and medication score, ACS, based on diary card records is the standard clinical parameter for the assessment of allergic disease severity and recommended by the World Allergy Organisation, WAO.
